Women w/ signs & symptoms of active allergic conditions or known history of allergic predisposition. Possible reduction in bone mineral density. Patients w/ additional risk factors of osteoporosis [eg, chronic alcohol abuse, smokers, long-term therapy w/ bone mineral density-reducing drugs (eg, anticonvulsants or corticoids), family history of osteoporosis, malnutrition]. May reveal presence of previously unknown gonadotroph cell pituitary adenoma; patients may present w/ pituitary apoplexy characterised by sudden headache, vomiting, visual impairment & ophthalmoplegia. Increased risk of incident depression. Closely monitor patients w/ known depression during therapy. Confirm if patient is not pregnant before prescribing triptorelin. Possible increased risk of multiple & ectopic pregnancies, pregnancy loss & congenital malformations. May increase risk of ovarian hyperstimulation syndrome (OHSS) & ovarian cysts. Monitor symptoms of severe OHSS cases (eg, abdominal pain & distension, severe ovarian enlargement, wt gain, dyspnoea, oliguria & GI symptoms including nausea, vomiting & diarrhoea); clinical evaluation may reveal hypovolaemia, haemoconcentration, electrolyte imbalances, ascites, haemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress & thromboembolic events. Monitor patients for at least 2 wk after hCG administration. Discontinue treatment if severe OHSS occurs. Higher risk of OHSS w/ use of GnRH agonists in combination w/ gonadotrophins. Ovarian cysts may occur during initial phase of treatment w/ GnRH agonist. Renal or hepatic impairment. Carefully examine potentially fertile women prior to treatment to exclude pregnancy. No relevant use in paed population.
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
